GGrantIndex
← Leaderboards

Rajesh Khanna

Indiana University Indianapolis

Google Scholar ↗PubMed ↗ORCID ↗
$12,550,368
Attributed
$18,343,598
Total exposure
13
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.8M · FY2013–25
$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,343,598 · 13

By mechanism

R01$8,425,443 · 5
RM1$4,820,611 · 1
RF1$2,022,237 · 1
R41$1,685,692 · 5
R61$1,389,615 · 1

Top collaborators

Others in their field

Top investigators on “Neurons”

Research focus

NeuronsIn VivoCellsSmall MoleculeProteinsMediatingChronic PainPainResponsePathogenesisRegulationPainful NeuropathyVoltageAfferent NeuronsLinkPathway InteractionsSpinal CordEffective TherapySpinal GangliaCollapsin Response Mediator Protein-2BindingPharmaceutical PreparationsSiteAnalgesics

Grant awards (27)

Dissection of NTSR2/calcium channel signaling as a non-opioid spinal analgesic mechanism for the treatment of high impact chronic pain$664,772
R01 · FY2025 · NS
Endosomal mechanisms signaling oral cancer pain$4,820,611
RM1 · FY2023 · DE
Validation of Neuropilin-1 Receptor Signaling in Nociceptive Processing$1,926,350
RF1 · FY2023 · NS · contact PI
Validation of Neuropilin-1 Receptor Signaling in Nociceptive Processing$95,887
RF1 · FY2023 · NS · contact PI
Antagonists of CRMP2 Phosphorylation for Chemotherapy-Induced Peripheral Neuropathy$902,822
R61 · FY2022 · NS · contact PI
Antagonists of CRMP2 Phosphorylation for Chemotherapy-Induced Peripheral Neuropathy$486,793
R61 · FY2022 · NS · contact PI
CRMP2, mitochondria, and Huntington’s disease$561,046
R01 · FY2021 · NS
Targeting the neuropilin-1 receptor (NRP-1)/VEGF-A axis for neuropathic pain$419,470
R41 · FY2021 · NS · contact PI
Inhibition of CaVα-β interaction with orally available small organic molecules for chronic pain$400,000
R41 · FY2021 · CA · contact PI
CRMP2 Phosphorylation: A Novel Target for Alzheimer's Disease?$383,750
R01 · FY2021 · NS · contact PI
CRMP2, Nav1.7 sodium channel, and chronic pain$382,864
R01 · FY2021 · DA · contact PI
Sentrin proteases, CRMP2 deSUMOylation, and Chronic Pain$198,936
R01 · FY2021 · NS · contact PI
Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain$858,381
R01 · FY2020 · NS · contact PI
Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain$796,630
R01 · FY2020 · NS · contact PI
CRMP2, mitochondria, and Huntington’s disease$561,046
R01 · FY2020 · NS
Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain$395,680
R01 · FY2020 · NS · contact PI
CRMP2, Nav1.7 sodium channel, and chronic pain$382,864
R01 · FY2020 · DA · contact PI
CRMP2, mitochondria, and Huntington’s disease$561,046
R01 · FY2019 · NS
CRMP2, Nav1.7 sodium channel, and chronic pain$382,864
R01 · FY2019 · DA · contact PI
Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy$341,527
R41 · FY2019 · NS · contact PI
Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain$224,696
R41 · FY2019 · DA · contact PI
CRMP2, mitochondria, and Huntington’s disease$561,046
R01 · FY2018 · NS
CRMP2, Nav1.7 sodium channel, and chronic pain$384,996
R01 · FY2018 · DA · contact PI
CRMP2, mitochondria, and Huntington’s disease$574,526
R01 · FY2017 · NS
CRMP2, Nav1.7 sodium channel, and chronic pain$384,996
R01 · FY2017 · DA · contact PI
Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates$299,999
R41 · FY2017 · CA · contact PI
The role of DAMPS in painful bladder syndrome$390,000
R01 · FY2013 · DK